Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3910432
Max Phase: Preclinical
Molecular Formula: C44H48Cl2N6O6S
Molecular Weight: 859.88
Molecule Type: Small molecule
Associated Items:
ID: ALA3910432
Max Phase: Preclinical
Molecular Formula: C44H48Cl2N6O6S
Molecular Weight: 859.88
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4cnc(OCCC5CCCO5)c(Cl)c4)c(Oc4cccc5[nH]ncc45)c3)CC2)=C(c2ccc(Cl)cc2)C1
Standard InChI: InChI=1S/C44H48Cl2N6O6S/c1-44(2)16-14-30(36(25-44)29-8-10-31(45)11-9-29)28-51-17-19-52(20-18-51)32-12-13-35(41(23-32)58-40-7-3-6-39-37(40)27-48-49-39)42(53)50-59(54,55)34-24-38(46)43(47-26-34)57-22-15-33-5-4-21-56-33/h3,6-13,23-24,26-27,33H,4-5,14-22,25,28H2,1-2H3,(H,48,49)(H,50,53)
Standard InChI Key: BIGFZWFFVCNYSU-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 859.88 | Molecular Weight (Monoisotopic): 858.2733 | AlogP: 8.91 | #Rotatable Bonds: 13 |
Polar Surface Area: 138.98 | Molecular Species: ACID | HBA: 10 | HBD: 2 |
#RO5 Violations: 2 | HBA (Lipinski): 12 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 4.13 | CX Basic pKa: 7.96 | CX LogP: 6.65 | CX LogD: 6.78 |
Aromatic Rings: 5 | Heavy Atoms: 59 | QED Weighted: 0.12 | Np Likeness Score: -1.05 |
1. (2015) Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases, |
Source(1):